A structured index of tech-law analyses, DPDP compliance reviews, and legal governance guidelines.
Over 90% of Indian businesses have not fully implemented the Digital Personal Data Protection Act, 2023. Not partially. Not almost. Fully. And on May 6, 2026, the Ministry of Electronics and Information Technology (MeitY) issued the recruitment notice for the Chairperson and Members of the Data Protection Board of India (DPBI) the very body that will investigate breaches, issue directions, and impose penalties against non-compliant organisations. The enforcer is being appointed. The countdown is no longer theoretical. If your organisation is still treating DPDP compliance as a future agenda item, this is one of your final warning.
An AI agent's rejected pull request triggered the first documented AI retaliation in open-source history. Here's what it means for developers, maintainers, and the future of software.
We are bribing our AIs. We have built the most powerful technology in human history on a foundation of do this, get reward. Do that, get punished. And we have dressed it up in mathematics so elegant that we forgot to ask whether the underlying logic is as clean as the equations suggest. We call it "reinforcement learning." We call it "feedback training." We call it "alignment through human preference optimization." But strip away the technical language, squint at what's actually happening and a much more familiar picture emerges, one that looks less like education and a lot more like sliding an envelope across a table.
Singapore's Ministry of Law published a 50-page Gen AI guide for legal professionals on March 6, 2026. Here is what it says and what Indian advocates need to act on now.
On March 20, 2026, the patent on semaglutide expired in India. Within 24 hours, at least five domestic drugmakers had launched generic versions of Novo Nordisk's Ozempic and Wegovy at prices up to 80% lower than the original. Sun Pharmaceutical launched its version for as low as Rs 750 for a weekly injection. Dr. Reddy's announced a target of 87 countries for generic semaglutide launches. The GLP-1 drug war in India had officially begun. But the more important story here is not about the drugs. It is about the law.
Select a core coordinate tag below to narrow down the legal treatises index.
Speak directly with our specialized team to structure corporate AI models, data systems, and policy guidelines.